NCT05386511Completed
Real-world Study of UTD1 in Chinese Advanced Breast Cancer
An Observational, Real-world Study Study of UTD1 in Chinese Advanced Breast Cancer
Source: ClinicalTrials.gov · Last updated 26 Feb 2024
Brief summary (registry, in English)
To evaluate the efficacy and safety of UTD1 in patients with advanced breast cancer.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 150 (actual)
- First submitted
- 18 May 2022
- Start date
- 1 Apr 2022
- Primary completion date
- 1 Feb 2024
- Lead sponsor
- Fudan University
- Diseases
- Metastatic breast cancer
- NCT number
- NCT05386511
What you commit to
- Study type: Observational
- Participants enrolled: 150
- From 1 Apr 2022 to the primary completion date, 1 Feb 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- 1.Incomplete medical history.
Who the study is looking for
- Patients aged over 18 years old.
- Metastatic breast cancer included unresectable locally advanced breast cancer, de novo stage IV breast cancer, and recurrent metastatic breast cancer.
- Plan to receive or has received UTD1 monotherapy or UTD1 based therapy
- Available medical history.
Age in the registry: 18 years to - · Sex: Female
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fudan University Shanghai Cancer Center Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.